Loading…
The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension
Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip...
Saved in:
Published in: | Basic & clinical pharmacology & toxicology 2015-10, Vol.117 (4), p.234-241 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 241 |
container_issue | 4 |
container_start_page | 234 |
container_title | Basic & clinical pharmacology & toxicology |
container_volume | 117 |
creator | Cau, Stefany B. A. Guimaraes, Danielle A. Rizzi, Elen Ceron, Carla S. Gerlach, Raquel F. Tanus‐Santos, Jose E. |
description | Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip (2K1C) hypertension‐induced left ventricular remodelling. Sham‐operated controls or 2K1C rats with hypertension received either vehicle or PDTC (100 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure was monitored every week. Histological assessment of left ventricles was carried out with haematoxylin/eosin sections, and fibrosis was quantified in picrosirius red‐stained sections. Oxidative stress was evaluated in heart samples with the dihydroethidium probe. Cardiac MMP activity was determined by in situ zymography, and cardiac MMP‐2 was assessed by immunofluorescence. 2K1C surgery significantly increased systolic blood pressure in the 2K1C vehicle. PDTC exerted antihypertensive effects after 2 weeks of treatment. Histology revealed increased left ventricular and septum wall thickness associated with augmented myocyte diameter in hypertensive rats, which were reversed by treatment with PDTC. Hypertensive rats developed pronounced cardiac fibrosis with increased interstitial collagen area, increased cardiac reactive oxygen species levels, gelatinase activity and MMP‐2 expression. PDTC treatment decreased these alterations. These findings show that PDTC modulates myocardial MMP‐2 expression and ameliorates cardiac remodelling in renovascular hypertension. These results suggest that interfering with MMP expression at transcriptional level may be an interesting strategy in the therapy of organ damage associated with hypertension. |
doi_str_mv | 10.1111/bcpt.12400 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1709466623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3797558641</sourcerecordid><originalsourceid>FETCH-LOGICAL-p3510-5d6e52178cad699686aa26a60e671315a1d823218ad733e9d28fb4bceddefae43</originalsourceid><addsrcrecordid>eNo9Uc1OGzEQtioqAimXPkBliXPAP7vezbGEApGSNkLhvJpdTxJTx956vZTceIQ-Rx-LJ6kDlLnM6Jtvfj9CPnN2xpOd100bz7jIGPtAjniRiVFRZvLgPZb5gBx33T1josg4OyQDkZdcFTw_In-XG6Tf-8YiBHoFTfSB_oS2hQs6dRtTmz2w2IXgrdHGIb00cWN8A6GGLUSki4AP6GJHJxC0gYbe4tZrtNa4NQWn6RxiMI90jhGs9W3wEY2DDp-f_gh61yZ3i-veQjTeUeNSvfMP0DUJCvRm12KI6LqU_EQ-rsB2ePLmh-Tu6ttycjOa_bieTr7ORq3MORvlWmEueFE2oNV4rEoFIBQohuliyXPguhRS8BJ0ISWOtShXdVY3qDWuADM5JKevfdOuv3rsYnXv--DSyIoXbJwppYRMrC9vrL7eoq7aYLYQdtX_1yYCfyX8NhZ373nOqr1o1V606kW06mKyWL5E8h8MCo-2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709466623</pqid></control><display><type>article</type><title>The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension</title><source>Wiley</source><creator>Cau, Stefany B. A. ; Guimaraes, Danielle A. ; Rizzi, Elen ; Ceron, Carla S. ; Gerlach, Raquel F. ; Tanus‐Santos, Jose E.</creator><creatorcontrib>Cau, Stefany B. A. ; Guimaraes, Danielle A. ; Rizzi, Elen ; Ceron, Carla S. ; Gerlach, Raquel F. ; Tanus‐Santos, Jose E.</creatorcontrib><description>Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip (2K1C) hypertension‐induced left ventricular remodelling. Sham‐operated controls or 2K1C rats with hypertension received either vehicle or PDTC (100 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure was monitored every week. Histological assessment of left ventricles was carried out with haematoxylin/eosin sections, and fibrosis was quantified in picrosirius red‐stained sections. Oxidative stress was evaluated in heart samples with the dihydroethidium probe. Cardiac MMP activity was determined by in situ zymography, and cardiac MMP‐2 was assessed by immunofluorescence. 2K1C surgery significantly increased systolic blood pressure in the 2K1C vehicle. PDTC exerted antihypertensive effects after 2 weeks of treatment. Histology revealed increased left ventricular and septum wall thickness associated with augmented myocyte diameter in hypertensive rats, which were reversed by treatment with PDTC. Hypertensive rats developed pronounced cardiac fibrosis with increased interstitial collagen area, increased cardiac reactive oxygen species levels, gelatinase activity and MMP‐2 expression. PDTC treatment decreased these alterations. These findings show that PDTC modulates myocardial MMP‐2 expression and ameliorates cardiac remodelling in renovascular hypertension. These results suggest that interfering with MMP expression at transcriptional level may be an interesting strategy in the therapy of organ damage associated with hypertension.</description><identifier>ISSN: 1742-7835</identifier><identifier>EISSN: 1742-7843</identifier><identifier>DOI: 10.1111/bcpt.12400</identifier><identifier>PMID: 25816715</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Animals ; Blood Pressure ; Collagen - metabolism ; Disease Models, Animal ; Fibrosis ; Heart Ventricles - drug effects ; Heart Ventricles - enzymology ; Heart Ventricles - pathology ; Heart Ventricles - physiopathology ; Hypertension, Renovascular - complications ; Hypertension, Renovascular - drug therapy ; Hypertension, Renovascular - enzymology ; Hypertension, Renovascular - pathology ; Hypertension, Renovascular - physiopathology ; Hypertrophy, Left Ventricular - enzymology ; Hypertrophy, Left Ventricular - etiology ; Hypertrophy, Left Ventricular - pathology ; Hypertrophy, Left Ventricular - physiopathology ; Hypertrophy, Left Ventricular - prevention & control ; Male ; Matrix Metalloproteinase 2 - metabolism ; NF-kappa B - antagonists & inhibitors ; NF-kappa B - metabolism ; Oxidative Stress - drug effects ; Pyrrolidines - pharmacology ; Rats, Wistar ; Thiocarbamates - pharmacology ; Time Factors ; Up-Regulation ; Ventricular Function, Left - drug effects ; Ventricular Remodeling - drug effects</subject><ispartof>Basic & clinical pharmacology & toxicology, 2015-10, Vol.117 (4), p.234-241</ispartof><rights>2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)</rights><rights>2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).</rights><rights>Copyright © 2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25816715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cau, Stefany B. A.</creatorcontrib><creatorcontrib>Guimaraes, Danielle A.</creatorcontrib><creatorcontrib>Rizzi, Elen</creatorcontrib><creatorcontrib>Ceron, Carla S.</creatorcontrib><creatorcontrib>Gerlach, Raquel F.</creatorcontrib><creatorcontrib>Tanus‐Santos, Jose E.</creatorcontrib><title>The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension</title><title>Basic & clinical pharmacology & toxicology</title><addtitle>Basic Clin Pharmacol Toxicol</addtitle><description>Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip (2K1C) hypertension‐induced left ventricular remodelling. Sham‐operated controls or 2K1C rats with hypertension received either vehicle or PDTC (100 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure was monitored every week. Histological assessment of left ventricles was carried out with haematoxylin/eosin sections, and fibrosis was quantified in picrosirius red‐stained sections. Oxidative stress was evaluated in heart samples with the dihydroethidium probe. Cardiac MMP activity was determined by in situ zymography, and cardiac MMP‐2 was assessed by immunofluorescence. 2K1C surgery significantly increased systolic blood pressure in the 2K1C vehicle. PDTC exerted antihypertensive effects after 2 weeks of treatment. Histology revealed increased left ventricular and septum wall thickness associated with augmented myocyte diameter in hypertensive rats, which were reversed by treatment with PDTC. Hypertensive rats developed pronounced cardiac fibrosis with increased interstitial collagen area, increased cardiac reactive oxygen species levels, gelatinase activity and MMP‐2 expression. PDTC treatment decreased these alterations. These findings show that PDTC modulates myocardial MMP‐2 expression and ameliorates cardiac remodelling in renovascular hypertension. These results suggest that interfering with MMP expression at transcriptional level may be an interesting strategy in the therapy of organ damage associated with hypertension.</description><subject>Animals</subject><subject>Blood Pressure</subject><subject>Collagen - metabolism</subject><subject>Disease Models, Animal</subject><subject>Fibrosis</subject><subject>Heart Ventricles - drug effects</subject><subject>Heart Ventricles - enzymology</subject><subject>Heart Ventricles - pathology</subject><subject>Heart Ventricles - physiopathology</subject><subject>Hypertension, Renovascular - complications</subject><subject>Hypertension, Renovascular - drug therapy</subject><subject>Hypertension, Renovascular - enzymology</subject><subject>Hypertension, Renovascular - pathology</subject><subject>Hypertension, Renovascular - physiopathology</subject><subject>Hypertrophy, Left Ventricular - enzymology</subject><subject>Hypertrophy, Left Ventricular - etiology</subject><subject>Hypertrophy, Left Ventricular - pathology</subject><subject>Hypertrophy, Left Ventricular - physiopathology</subject><subject>Hypertrophy, Left Ventricular - prevention & control</subject><subject>Male</subject><subject>Matrix Metalloproteinase 2 - metabolism</subject><subject>NF-kappa B - antagonists & inhibitors</subject><subject>NF-kappa B - metabolism</subject><subject>Oxidative Stress - drug effects</subject><subject>Pyrrolidines - pharmacology</subject><subject>Rats, Wistar</subject><subject>Thiocarbamates - pharmacology</subject><subject>Time Factors</subject><subject>Up-Regulation</subject><subject>Ventricular Function, Left - drug effects</subject><subject>Ventricular Remodeling - drug effects</subject><issn>1742-7835</issn><issn>1742-7843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNo9Uc1OGzEQtioqAimXPkBliXPAP7vezbGEApGSNkLhvJpdTxJTx956vZTceIQ-Rx-LJ6kDlLnM6Jtvfj9CPnN2xpOd100bz7jIGPtAjniRiVFRZvLgPZb5gBx33T1josg4OyQDkZdcFTw_In-XG6Tf-8YiBHoFTfSB_oS2hQs6dRtTmz2w2IXgrdHGIb00cWN8A6GGLUSki4AP6GJHJxC0gYbe4tZrtNa4NQWn6RxiMI90jhGs9W3wEY2DDp-f_gh61yZ3i-veQjTeUeNSvfMP0DUJCvRm12KI6LqU_EQ-rsB2ePLmh-Tu6ttycjOa_bieTr7ORq3MORvlWmEueFE2oNV4rEoFIBQohuliyXPguhRS8BJ0ISWOtShXdVY3qDWuADM5JKevfdOuv3rsYnXv--DSyIoXbJwppYRMrC9vrL7eoq7aYLYQdtX_1yYCfyX8NhZ373nOqr1o1V606kW06mKyWL5E8h8MCo-2</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Cau, Stefany B. A.</creator><creator>Guimaraes, Danielle A.</creator><creator>Rizzi, Elen</creator><creator>Ceron, Carla S.</creator><creator>Gerlach, Raquel F.</creator><creator>Tanus‐Santos, Jose E.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201510</creationdate><title>The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension</title><author>Cau, Stefany B. A. ; Guimaraes, Danielle A. ; Rizzi, Elen ; Ceron, Carla S. ; Gerlach, Raquel F. ; Tanus‐Santos, Jose E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p3510-5d6e52178cad699686aa26a60e671315a1d823218ad733e9d28fb4bceddefae43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Blood Pressure</topic><topic>Collagen - metabolism</topic><topic>Disease Models, Animal</topic><topic>Fibrosis</topic><topic>Heart Ventricles - drug effects</topic><topic>Heart Ventricles - enzymology</topic><topic>Heart Ventricles - pathology</topic><topic>Heart Ventricles - physiopathology</topic><topic>Hypertension, Renovascular - complications</topic><topic>Hypertension, Renovascular - drug therapy</topic><topic>Hypertension, Renovascular - enzymology</topic><topic>Hypertension, Renovascular - pathology</topic><topic>Hypertension, Renovascular - physiopathology</topic><topic>Hypertrophy, Left Ventricular - enzymology</topic><topic>Hypertrophy, Left Ventricular - etiology</topic><topic>Hypertrophy, Left Ventricular - pathology</topic><topic>Hypertrophy, Left Ventricular - physiopathology</topic><topic>Hypertrophy, Left Ventricular - prevention & control</topic><topic>Male</topic><topic>Matrix Metalloproteinase 2 - metabolism</topic><topic>NF-kappa B - antagonists & inhibitors</topic><topic>NF-kappa B - metabolism</topic><topic>Oxidative Stress - drug effects</topic><topic>Pyrrolidines - pharmacology</topic><topic>Rats, Wistar</topic><topic>Thiocarbamates - pharmacology</topic><topic>Time Factors</topic><topic>Up-Regulation</topic><topic>Ventricular Function, Left - drug effects</topic><topic>Ventricular Remodeling - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cau, Stefany B. A.</creatorcontrib><creatorcontrib>Guimaraes, Danielle A.</creatorcontrib><creatorcontrib>Rizzi, Elen</creatorcontrib><creatorcontrib>Ceron, Carla S.</creatorcontrib><creatorcontrib>Gerlach, Raquel F.</creatorcontrib><creatorcontrib>Tanus‐Santos, Jose E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Basic & clinical pharmacology & toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cau, Stefany B. A.</au><au>Guimaraes, Danielle A.</au><au>Rizzi, Elen</au><au>Ceron, Carla S.</au><au>Gerlach, Raquel F.</au><au>Tanus‐Santos, Jose E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension</atitle><jtitle>Basic & clinical pharmacology & toxicology</jtitle><addtitle>Basic Clin Pharmacol Toxicol</addtitle><date>2015-10</date><risdate>2015</risdate><volume>117</volume><issue>4</issue><spage>234</spage><epage>241</epage><pages>234-241</pages><issn>1742-7835</issn><eissn>1742-7843</eissn><abstract>Imbalanced matrix metalloproteinase (MMP) activity is involved in hypertensive cardiac hypertrophy. Pharmacological inhibition of nuclear factor kappaB (NF‐кB) with pyrrolidine dithiocarbamate (PDTC) can prevent MMP up‐regulation. We suggested that treatment with PDTC could prevent 2‐kidney, 1‐clip (2K1C) hypertension‐induced left ventricular remodelling. Sham‐operated controls or 2K1C rats with hypertension received either vehicle or PDTC (100 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure was monitored every week. Histological assessment of left ventricles was carried out with haematoxylin/eosin sections, and fibrosis was quantified in picrosirius red‐stained sections. Oxidative stress was evaluated in heart samples with the dihydroethidium probe. Cardiac MMP activity was determined by in situ zymography, and cardiac MMP‐2 was assessed by immunofluorescence. 2K1C surgery significantly increased systolic blood pressure in the 2K1C vehicle. PDTC exerted antihypertensive effects after 2 weeks of treatment. Histology revealed increased left ventricular and septum wall thickness associated with augmented myocyte diameter in hypertensive rats, which were reversed by treatment with PDTC. Hypertensive rats developed pronounced cardiac fibrosis with increased interstitial collagen area, increased cardiac reactive oxygen species levels, gelatinase activity and MMP‐2 expression. PDTC treatment decreased these alterations. These findings show that PDTC modulates myocardial MMP‐2 expression and ameliorates cardiac remodelling in renovascular hypertension. These results suggest that interfering with MMP expression at transcriptional level may be an interesting strategy in the therapy of organ damage associated with hypertension.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>25816715</pmid><doi>10.1111/bcpt.12400</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1742-7835 |
ispartof | Basic & clinical pharmacology & toxicology, 2015-10, Vol.117 (4), p.234-241 |
issn | 1742-7835 1742-7843 |
language | eng |
recordid | cdi_proquest_journals_1709466623 |
source | Wiley |
subjects | Animals Blood Pressure Collagen - metabolism Disease Models, Animal Fibrosis Heart Ventricles - drug effects Heart Ventricles - enzymology Heart Ventricles - pathology Heart Ventricles - physiopathology Hypertension, Renovascular - complications Hypertension, Renovascular - drug therapy Hypertension, Renovascular - enzymology Hypertension, Renovascular - pathology Hypertension, Renovascular - physiopathology Hypertrophy, Left Ventricular - enzymology Hypertrophy, Left Ventricular - etiology Hypertrophy, Left Ventricular - pathology Hypertrophy, Left Ventricular - physiopathology Hypertrophy, Left Ventricular - prevention & control Male Matrix Metalloproteinase 2 - metabolism NF-kappa B - antagonists & inhibitors NF-kappa B - metabolism Oxidative Stress - drug effects Pyrrolidines - pharmacology Rats, Wistar Thiocarbamates - pharmacology Time Factors Up-Regulation Ventricular Function, Left - drug effects Ventricular Remodeling - drug effects |
title | The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase‐2 Up‐Regulation in Renovascular Hypertension |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T05%3A30%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Nuclear%20Factor%20kappaB%20Inhibitor%20Pyrrolidine%20Dithiocarbamate%20Prevents%20Cardiac%20Remodelling%20and%20Matrix%20Metalloproteinase%E2%80%902%20Up%E2%80%90Regulation%20in%20Renovascular%20Hypertension&rft.jtitle=Basic%20&%20clinical%20pharmacology%20&%20toxicology&rft.au=Cau,%20Stefany%20B.%20A.&rft.date=2015-10&rft.volume=117&rft.issue=4&rft.spage=234&rft.epage=241&rft.pages=234-241&rft.issn=1742-7835&rft.eissn=1742-7843&rft_id=info:doi/10.1111/bcpt.12400&rft_dat=%3Cproquest_pubme%3E3797558641%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p3510-5d6e52178cad699686aa26a60e671315a1d823218ad733e9d28fb4bceddefae43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1709466623&rft_id=info:pmid/25816715&rfr_iscdi=true |